The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma

Lijun Hu; Ze Kong; Qinghong Meng; Jianlin Wang; Mengyun Zhou; Jingping Yu; Xiaodong Jiang

doi:10.12659/MSM.927221

27 November 2020 : Clinical Research

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma

Lijun Hu^1ABCDEF*, Ze Kong^1BCDF, Qinghong Meng^1BCD, Jianlin Wang^1BCF, Mengyun Zhou^1BC, Jingping Yu^1ACEG, Xiaodong Jiang^2ACEG

DOI: 10.12659/MSM.927221

Med Sci Monit 2020; 26:e927221

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Comparison of overall survival (OS) between the chemoradiotherapy plus Apatinib (Apatinib) group and the concurrent chemoradiotherapy only (CCRT) group. Group 1: Apatinib group; Group 0: CCRT group.

Back to the Article

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma

Your Privacy